Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

2.29AUD
23 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.29
Open
$2.31
Day's High
$2.38
Day's Low
$2.27
Volume
517,284
Avg. Vol
638,523
52-wk High
$2.73
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease
Tuesday, 7 Mar 2017 06:00am EST 

Mesoblast Ltd : FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease .Mesoblast Ltd - Enrollment in phase 3 trial is expected to complete mid-2017 with a top-line read out in 2H CY 2017.  Full Article

Mesoblast says US FDA grants fast track designation for GVHD
Monday, 6 Mar 2017 05:54pm EST 

Mesoblast Ltd : FDA grants Mesoblast fast track designation for GVHD .FDA grants fast track designation for Mesoblast's cell therapy in children with Acute Graft Versus Host Disease.  Full Article

Mesoblast Ltd says Co and Mallinckrodt enter into agreement
Thursday, 22 Dec 2016 04:54pm EST 

Mesoblast Ltd : Asx alert-Mesoblast and Mallinckrodt enter into agreement-MSB.AX . Mallinckrodt will have exclusive period of up to 9 months to conclude commercial,development agreements for 2 product candidates in all territories outside of Japan and China .Mallinckrodt will purchase approximately 20.04 million of Mesoblast's ordinary shares at a price of A$1.4761 per share.  Full Article

Mesoblast appoints Bill Burns as vice chairman
Wednesday, 31 Aug 2016 07:49pm EDT 

Mesoblast Ltd :Mesoblast appoints Bill Burns as vice chairman Full Article

Mesoblast reports Q4 earnings per share $0.1278
Wednesday, 24 Aug 2016 06:41pm EDT 

Mesoblast Ltd : Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016 .Q4 earnings per share $0.1278.  Full Article

Mesoblast provides update on global heart failure program
Monday, 13 Jun 2016 06:55pm EDT 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

Mesoblast says co received $6.2 mln from Australian government for R&D
Thursday, 19 May 2016 07:55pm EDT 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

Mesoblast Ltd announces pricing of public offering on Nasdaq
Friday, 13 Nov 2015 08:39am EST 

Mesoblast Ltd:Says initial public offering of 7.5 million ads priced at $8.00/ADS.  Full Article

Celgene and Mesoblast extend agreement
Thursday, 15 Oct 2015 07:50pm EDT 

Mesoblast:Says it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal.Agreement with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.  Full Article

Mesoblast Limited announces positive trial results of mesoblast cell therapy in patients with diabetes and advanced chronic kidney disease
Monday, 8 Jun 2015 06:38pm EDT 

Mesoblast Limited:Announces that results from the company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe.Says it reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.  Full Article

More From Around the Web

BRIEF-Mesoblast updates on durable three year outcomes in disc disease

* Mesoblast says 36-month results from randomized, placebo-controlled 100- patient phase 2 trial of allogeneic mpcs in patients with chronic low back pain